Skip to content
Calculator
Evidence: HighProtein, not a peptideFDA Approved60-amino-acid proteinFDA-approved 2009 · KalbitorBoxed warning

Ecallantide

A kallikrein blocker for hereditary angioedema attacks

Ecallantide is a 60-amino-acid recombinant protein that blocks plasma kallikrein, the enzyme that releases bradykinin during hereditary angioedema attacks. Approved as Kalbitor in 2009, it is injected under the skin during an attack, but only by a healthcare professional because of a risk of anaphylaxis.

Manufacturer's recommended dosing (FDA label): 30 mg (3 mL) as three 10 mg (1 mL) injections; if the attack persists, another 30 mg may be given within 24 hours, Per attack, Subcutaneous Details ↓

Overview

What is it?

Hereditary angioedema causes recurrent attacks of swelling of the skin, gut and airway, driven by bradykinin. Ecallantide blocks plasma kallikrein, the enzyme that releases bradykinin, and so treats an attack once it has started. At 60 amino acids it is a small protein rather than a peptide by FDA's definition, which is why it was licensed as a biologic. It is approved for people aged 12 and older.

In the EDEMA4 trial of 72 patients with moderate to severe attacks, the median treatment outcome score at four hours was 50 on ecallantide against 0 on placebo, with no treatment-related serious adverse events. The EDEMA3 trial found a similar four-hour benefit.

Throat swelling is the attack that kills, and pooled data cover it. Across four studies, 98 patients received ecallantide for 220 laryngeal attacks; the median time to significant improvement was 185 minutes, and one attack needed intubation. Younger patients were pooled the same way: 25 patients aged 9 to 17, treated for 62 attacks, improved more at four hours than those on placebo and reached near-complete resolution in a median of 181 minutes.

Swelling caused by ACE inhibitors is also driven by bradykinin, so ecallantide was tried there. A small emergency department pilot found 31% on ecallantide against 21% on placebo ready for discharge within four hours, and a larger trial of 79 patients found no significant difference. It is not approved for that use.

Repeat use held up. In a continuation study, 147 patients were treated for 625 attacks with no sign of the drug losing effect, and in the phase 3 trials worsening after an initial response was uncommon and mostly judged relapse rather than rebound. Ecallantide was also tested to reduce bleeding in heart surgery on bypass; that trial was stopped early because more patients died on ecallantide than on tranexamic acid (12% against 4%).

Its limitation is anaphylaxis. Across 230 patients and 1,045 doses, 3.5% had reactions meeting criteria for anaphylaxis, none on first exposure and all within an hour. The label carries a boxed warning and requires administration by a healthcare professional able to manage anaphylaxis. Its half-life is about two hours.

30 mg
Three 10 mg injections per attack
Kalbitor label
185 min
Median to improvement, laryngeal attacks
220 attacks · PMID 23548529
3.5%
Anaphylaxis across 1,045 doses
Boxed warning · PMID 25609335
Science

Mechanism of Action

Ecallantide is a 60-amino-acid Kunitz-domain protein, engineered from tissue factor pathway inhibitor, that blocks plasma kallikrein and so cuts off the release of bradykinin.

🎯

Plasma kallikrein

Binds and inhibits plasma kallikrein, the enzyme that cleaves high-molecular-weight kininogen to release bradykinin.

💧

Less bradykinin, less leakage

Bradykinin opens blood vessels and makes them leak; blocking its release treats the swelling of an attack.

⏱️

Short-lived

After a 30 mg dose, levels peak at 2 to 3 hours and fall with a half-life of about 2 hours; it is cleared partly by the kidneys (label).

Evidence

Published Research

The trials and safety data behind ecallantide, from their PubMed abstracts.

Human2010

EDEMA4: phase 3

In 72 patients with acute attacks, the median treatment outcome score at 4 hours was 50.0 on ecallantide against 0.0 on placebo (P = 0.004), with symptom severity improving more; there were no deaths, treatment-related serious adverse events or withdrawals for adverse events.

PMID: 20818887
Human2015

Not for ACE-inhibitor angioedema

In 79 emergency patients with angioedema from ACE inhibitors, discharge criteria were met by 72% on placebo and 85% to 89% on ecallantide 10 to 60 mg, a difference that was not significant.

PMID: 25182544
Human2013

How often a second dose is needed

Across 732 hereditary angioedema attacks in 179 patients, one 30 mg dose sufficed for 88%; a second dose was needed most often for peripheral attacks (16.5%).

PMID: 23548526
Human2013

Laryngeal attacks

Pooled from four studies, 98 patients received ecallantide for 220 laryngeal attacks; median time to significant improvement was 185 minutes, one attack needed intubation, and there were 2 anaphylactic reactions, both followed by full recovery.

PMID: 23548529
Human2013

Patients under 18

In 25 patients aged 9 to 17 treated for 62 attacks, symptom severity fell more at four hours than on placebo (MSCS -1.4 against -0.9; TOS 73.9 against 45.0), median time to near-complete resolution was 181 minutes, and no treatment-related serious adverse events occurred.

PMID: 23878046
Human2015

ACE-inhibitor angioedema pilot

In a triple-blind emergency department pilot of ACE-inhibitor angioedema not helped by standard therapy, 31% on ecallantide against 21% on placebo met discharge criteria within four hours, a difference with a confidence interval spanning zero (-14% to 34%).

PMID: 25601538
Human2013

Repeated attacks: continuation study

In an open-label continuation study, 147 patients were treated for 625 attacks with no sign of reduced effect on repeat use; 8 patients (5.4%) had possible hypersensitivity reactions, 6 of which met criteria for anaphylaxis.

PMID: 23484891
Human2012

Rebound and relapse

Of 70 ecallantide-treated patients in the phase 3 trials, 42 improved enough by four hours to be assessed; among nine who worsened by 24 hours, one was possible rebound and three possible or likely relapse.

PMID: 22765833
Human2012

Cardiac surgery: stopped early

In 218 patients having high-bleeding-risk cardiac surgery, the trial was stopped early when 30-day mortality was 12% on ecallantide against 4% on tranexamic acid; ecallantide patients also needed more red cell transfusion (median 900 against 300 mL).

PMID: 21724197
Review2010

EDEMA3 and the evidence base

A review describing ecallantide as a selective, reversible plasma kallikrein inhibitor and summarising EDEMA3, in which a single 30 mg dose produced a significantly greater symptom response at 4 hours than placebo.

PMID: 20614949
Human2015

Anaphylaxis after ecallantide

Among 230 patients given 1,045 doses, 8 (3.5%) had reactions meeting anaphylaxis criteria, none on first exposure, all within 1 hour, and all resolved with standard treatment.

PMID: 25609335
Review2015

Role in managing attacks

A review of hereditary angioedema treatment placing ecallantide among on-demand therapies for acute attacks, alongside long-term and short-term prophylaxis.

PMID: 25931832
Animal2024

Albumin fusion in mice

Fusing recombinant ecallantide to human albumin raised its exposure in mice 3.4- to 3.6-fold without weakening kallikrein inhibition; clearance ran mainly through the LRP1 receptor rather than albumin recycling.

PMID: 38844246
Dosing

Dosing Data

Kalbitor is given during an attack as 30 mg under the skin, split into three 10 mg injections, by a healthcare professional with support to manage anaphylaxis.

Boxed warning for anaphylaxis. Given only by a healthcare professional; not for self-injection.
ProtocolDoseFrequencyDurationRoute
Label: acute attack of hereditary angioedema, age 12+ Approved labelKALBITOR (ecallantide) injection Prescribing Information, boxed warning and sections 1, 2 and 12.3 (DailyMed version 19, effective July 1, 2025)30 mg (3 mL) as three 10 mg (1 mL) injections; if the attack persists, another 30 mg may be given within 24 hoursPer attackSingle dose, with one repeat allowed within 24 hoursSubcutaneous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Fixed dose
Ecallantide is a fixed 30 mg dose given as three 1 mL injections; there is nothing to calculate.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

The approved product, as its label describes it:

  • Kalbitor (ecallantide injection): KALBITOR is a clear, colorless liquid free of preservatives. Each vial of KALBITOR contains ecallantide at a concentration of 10 mg/mL. Single-dose glass vial containing 10 mg/mL of ecallantide as a solution for injection. Forms the label lists: vials.

Source: Kalbitor (ecallantide injection) label, section 3 (DailyMed version 19, effective July 1, 2025).

Mixing a vial: a worked example

Nothing to mix: the label gives Kalbitor (ecallantide injection) as vials, ready to use.

Source: Kalbitor (ecallantide injection) label, sections 2, 3 and 16 (DailyMed version 19, effective July 1, 2025).

Storage before and after mixing

Before mixing or first use: “NDC (): 3 single-dose vials in 1 carton KALBITOR should be kept refrigerated (2°C to 8°C/36°F to 46°F).” “Vials removed from refrigeration should be stored below 86°F/30°C and used within 14 days or returned to refrigeration until use.”

After mixing or first use: the label sentences we read say nothing separate about this.

Source: Kalbitor (ecallantide injection) label, sections 16 and 2 (DailyMed version 19, effective July 1, 2025).

How it is taken

As the approved label gives it: Subcutaneous (Per attack; Label: acute attack of hereditary angioedema, age 12+).

Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: a half-life of elimination half-life 2.0 ± 0.5 hours. After about five half-lives almost none is left.

How long the doses were given: Label: acute attack of hereditary angioedema, age 12+: Single dose, with one repeat allowed within 24 hours.

When effects appear: unknown; no source on this page gives a time to effect for Ecallantide. Results reported in the studies are under Published Research.

Source: half-life: Kalbitor prescribing information, section 12.3 (DailyMed set f56aec67, effective July 1, 2025); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Anaphylaxis in 3.5% of patients across 1,045 doses; No treatment-related serious adverse events in EDEMA4. Full list and cautions ↓

Boxed warning on the label: Anaphylaxis.

When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Ecallantide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: Kalbitor (ecallantide injection) label, boxed warning and section 5 (DailyMed version 19, effective July 1, 2025); the Side Effects section below (“From the studies above”).

Interactions

Unknown: a PubMed search for human interaction studies of Ecallantide (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.

Every peptide's record, with its source: the interaction matrix.

Checking what you bought

Unknown: no published independent test of Ecallantide products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: FDA Approved (Approved in the US as Kalbitor, BLA 125277, on December 1, 2009, for acute attacks of hereditary angioedema). Sport: Not on the 2026 List.

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● Anaphylaxis in 3.5% of patients across 1,045 doses
● No treatment-related serious adverse events in EDEMA4

Contraindications & Cautions

Warnings from the Kalbitor label (DailyMed, effective July 1, 2025).

● Boxed warning: anaphylaxis; administer only where anaphylaxis can be managed
● Hypersensitivity reactions
Questions

Frequently Asked Questions

?Is ecallantide a peptide?

It is a 60-amino-acid protein. FDA treats chains longer than 40 amino acids as proteins, which is why ecallantide was licensed as a biologic.

?Why must a healthcare professional give it?

Because of anaphylaxis: about 3.5% of patients had anaphylactic reactions in pooled data, and the label requires administration where anaphylaxis can be treated.

?What does ecallantide treat?

Acute attacks of hereditary angioedema in people 12 and older, by blocking the enzyme that releases bradykinin.

?How is ecallantide given?

The label dose is 30 mg as three 10 mg injections under the skin during an attack; if the attack persists, another 30 mg may be given within 24 hours, always by a healthcare professional.

?How quickly does ecallantide work?

In the EDEMA4 trial, the estimated time to significant improvement was 165 minutes on ecallantide against more than 240 minutes on placebo, a difference that was not statistically significant; the main four-hour symptom score did improve significantly.

?Does ecallantide work for throat swelling?

Pooled data from four studies covered 220 laryngeal attacks in 98 patients, with a median of 185 minutes to significant improvement; one attack needed intubation.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA (openFDA): KALBITOR, BLA 125277 (December 1, 2009). Read October 3, 2026.
  2. [fda-pi] FDA. Kalbitor (ecallantide) US prescribing information (DailyMed set f56aec67-c662-477c-b866-bfc23e8809cf, version 19, effective July 1, 2025). Read October 3, 2026.
  3. [clinical-trial] Cicardi M, et al. "Ecallantide for the treatment of acute attacks in hereditary angioedema." N Engl J Med, 2010;363(6):523-31. PMID: 20818887.
  4. [pubmed] Garnock-Jones KP. "Ecallantide: in acute hereditary angioedema." Drugs, 2010;70(11):1423-31. PMID: 20614949.
  5. [pubmed] Craig TJ, et al. "Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks." J Allergy Clin Immunol Pract, 2015;3(2):206-212.e4. PMID: 25609335.
  6. [pubmed] Duffey H, et al. "Management of acute attacks of hereditary angioedema: role of ecallantide." J Blood Med, 2015;6:115-23. PMID: 25931832.
  7. [clinical-trial] Lewis LM, et al. "Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial." Ann Emerg Med, 2015;65(2):204-13. PMID: 25182544.
  8. [pubmed] Li HH, et al. "Analysis of hereditary angioedema attacks requiring a second dose of ecallantide." Ann Allergy Asthma Immunol, 2013;110(3):168-72. PMID: 23548526.
  9. [pubmed] Sheffer AL, et al. "Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks." Ann Allergy Asthma Immunol, 2013;110(3):184-188.e2. PMID: 23548529.
  10. [pubmed] MacGinnitie AJ, et al. "Use of ecallantide in pediatric hereditary angioedema." Pediatrics, 2013;132(2):e490-7. PMID: 23878046.
  11. [pubmed] Bernstein JA, et al. "Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department." Ann Allergy Asthma Immunol, 2015;114(3):245-9. PMID: 25601538.
  12. [pubmed] Al-Adimi G, et al. "Extension of the circulatory half-life of recombinant ecallantide via albumin fusion without loss of anti-kallikrein activity." J Biotechnol, 2024;391:11-19. PMID: 38844246.
  13. [pubmed] Lumry WR, et al. "Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study." Allergy Asthma Proc, 2013;34(2):155-61. PMID: 23484891.
  14. [pubmed] Bernstein JA, et al. "Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema." Allergy, 2012;67(9):1173-80. PMID: 22765833.
  15. [pubmed] Bokesch PM, et al. "A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial)." J Thorac Cardiovasc Surg, 2012;143(5):1022-9. PMID: 21724197.

Sources & Citations

Studies were read from their PubMed abstracts; the Kalbitor label (DailyMed version 19, effective July 1, 2025) was read October 6, 2026.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-03